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Background: Cancer has become a global burden due to its high incidence and mortality rates, with an estimated
14.1 million cancer cases reported worldwide in 2012 particularly as a result of metastasis. Metastasis involves two crucial
steps: adhesion and invasion, and the non-integrin receptor; the 37-kDa/67-kDa laminin receptor precursor/ high affinity
laminin receptor (LRP/LR) has been shown to be overexpressed on the surface of tumorigenic cells, thus being implicated
in the enhancement of these two crucial steps. The current study investigated the role of LRP/LR on the aggressiveness
of pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) cells with respect to their adhesive and invasive potential.
Methods: AsPC-1 and IMR-32 cells were utilized as the experimental cell lines for the study. Cell surface LRP/LR levels
were visualised and quantified on the experimental and control (MCF-7) cell lines via confocal microscopy and flow
cytometry, respectively. Total LRP/LR levels in the cell lines were assessed by Western blotting and the adhesive and
invasive potential of the above-mentioned cell lines was determined before and after supplementation with the anti-LRP/
LR specific antibody IgG1-iS18. Statistical significance of the data was confirmed via the use of the two-tailed student’s
t-test and Pearson’s correlation coefficient.
Results: Flow cytometry revealed that AsPC-1 and IMR-32 cells displayed significantly higher cell surface LRP/LR levels in
comparison to the MCF-7 control cell line. However, Western blotting and subsequent densitometric analysis revealed
that all three tumorigenic cell lines displayed no significant difference in total LRP/LR levels. The treatment of AsPC-1 and
IMR-32 cells with IgG1-iS18 caused a significant reduction in the adhesive and invasive potential of the cells to laminin-1
and through the ECM-like Matrigel™, respectively. Pearson’s correlation coefficients indicated a high correlation, thus
suggesting a directly proportional relationship between cell surface LRP/LR levels and the adhesive and invasive potential
of AsPC-1 and IMR-32 cells.
Conclusion: These findings suggest that through the interference of the LRP/LR-laminin-1 interaction, the anti-LRP/LR
specific antibody IgG1-iS18 may act as an alternative therapeutic tool for the treatment of metastatic pancreatic cancer
and neuroblastoma.
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Cancer is defined as the uncontrolled proliferation of
body cells due to the diminished levels of apoptosis or
programmed cell death, thus resulting in abnormal cel-
lular growth [1, 2]. Cancer is implicated as the primary
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tries [3]. According to the World Cancer Research Fund
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wide in 2012 and this number is expected to increase to
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study, two cancer types are of importance namely pan-
creatic cancer which is an aggressive cancer type as it is
asymptomatic in the early stages and upon diagnoses the
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diagnosed cancer in 2012 with approximately 338 000
cases being diagnosed. Neuroblastoma is an aggressive
and malignant cancer type with 50% of all cases being
classified as high risk upon diagnosis as the disease has
metastasised. Neuroblastoma most commonly affects in-
fants and young children and it was ranked as the 17th
most diagnosed cancer types in 2012 with approximately
256 000 cases being diagnosed [4]. Due to these alarming
statistics, it is therefore crucial to develop novel thera-
peutic strategies for the treatment of cancer and in par-
ticular metastatic pancreatic cancer and neuroblastoma.
The 37-kDa/67-kDa laminin receptor (LRP/LR) is a 295
amino acid, transmembrane receptor consisting of three
domains; the N-terminal intracellular cytosolic domain,
the transmembrane domain and the C-terminal extracel-
lular domain which contains binding sites for laminin-1,
carbohydrates, elastin, prion proteins and IgG antibodies
[5–7]. The 37-kDa LRP is thought to be the precursor of
the 67-kDa high-affinity laminin receptor LR, however the
exact mechanism by which the precursor forms the recep-
tor is unknown [8]. The receptor is seen to be overex-
pressed on the surface of tumorigenic cells such as
cervical, lung, prostate and colon [9, 10], breast and
oesophageal [11] and liver cancer cells [12], thus serving
many physiological functions such as signal transduction,
cell cycle progression, cell migration, cell-matrix adhesion,
cell viability and proliferation [13–15]. LRP/LR is also as-
sociated with the process of Aβ- generation in Alzheimer’s
disease [16, 17] as well as enhancing telomerase activity
which is seen to play a role in disease progression and
chemotherapy resistance in some cancers [18]. LRP/LR
overexpression directly promotes the adhesion and inva-
sion of tumorigenic cell lines via the process of metastasis.
Metastasis is responsible for secondary tumor formation
thus accounting for 90% of cancer- associated deaths [11].
LRP/LR has a high binding affinity for the extracellular
matrix (ECM) protein; laminin-1 [14]. Laminins make up
the majority of the non-collagenous glycoprotein compo-
nent when localized in the basement membrane [19].
Laminins support the promotion of the invasive pheno-
type of several tumorigenic cells as they are involved in
significant biological activities such as cell attachment,
growth and migration [19]. The main event responsible
for tumor invasion is the interaction of cancer cells; in
particular LRP/LR with laminin-1, therefore inducing pro-
teolytic activity which involves type IV collagenase which
hydrolyses type-IV collagen in the basal lamina, resulting
in the metastatic spread of the cancer cells to distant tis-
sues in the body [19].
Hindering the LRP/LR-laminin-1 interaction may be
considered an essential tool in treating metastatic can-
cer. This may be achieved by blocking LRP/LR with
IgG1-iS18. IgG1-iS18 is the full length versionimmunoglobulin G1 (IgG1)-iS18 of the single-chain
anti-LRP/LR antibody scFv iS18. It is a monoclonal anti-
LRP/LR specific antibody which was designed to specif-
ically target the LRP/LR-laminin-1 interaction and it is
characteristic of having a high stability and long half-life
of up to 21 days in blood. This approach has therefore
been shown to significantly reduce the adhesive and in-
vasive potential of several tumorigenic cells [10–12].
In this study, we investigated whether the anti-LRP/LR
specific antibody IgG1-iS18 is capable of impeding the
adhesive and invasive potential of pancreatic cancer
(AsPC-1) and neuroblastoma (IMR-32) cells.
Methods
Cell culture
Poorly invasive, human breast adenocarcinoma (MCF-7)
cells, human pancreatic adenocarcinoma (AsPC-1) cells
and human neuroblastoma (IMR-32) cells were culti-
vated in Dulbecco’s Modified Eagle Medium (DMEM),
RPMI 1640 and Minimum Essential Media (MEM), re-
spectively. Each cell culture medium was supplemented
with 10% FCS and 1% penicillin/ streptomycin, with
additional amino acids, vitamins and salts being added
as required for complete growth media. All cell lines
were cultivated at 37 °C and 5% CO2.
Cells were seeded and sub-cultured at appropriate di-
lutions. The cultured cells were washed and detached
using phosphate buffered saline (PBS) and 1X Trypsin/
Versene, respectively.
Reagents and antibodies
Laminin-1 (10 μg/ml) obtained from BD Biosciences was
used for cell adhesion assays.
Matrigel™ matrix used in cell invasion assays was ex-
tracted from the Engelbreth-Holm-Swarm (EHS) mouse
sarcoma a tumor rich in extracellular matrix proteins.
Once isolated, the Matrigel™ constitutes of approximately
60% laminin, 30% collagen IV, 8% entactin and several
growth factors. It was obtained from Corning Inc.
Chloramphenicol acetyltransferase (CAT) antibody
was used as the negative control and it was obtained
from Sigma-Aldrich.
IgG1-iS18 was used as the treatment antibody (positive
control) and it was recombinantly produced in a mamma-
lian expression system as described by Zuber et al., (2008).
Confocal microscopy
In order to qualitatively visualize the localization of
LRP/LR on the cell surface, confocal microscopy was
employed. The cells were first seeded onto coverslips
and allowed to reach an approximate confluency of 75%
before being fixed for 15 min in 4% paraformaldehyde
(PFA). This was followed by five PBS washes and the
addition of the primary antibody IgG1-iS18 (1:100)
Rebelo et al. BMC Cancer  (2016) 16:917 Page 3 of 11diluted in 0.5% BSA. Post an overnight incubation at
4 °C, the coverslips were rinsed thrice in PBS/BSA.
After the addition of the goat anti-human IgG FITC-
coupled secondary antibody (abcam) that had been diluted
in 0.5% BSA, a further 1 h incubation at 4 °C was allowed.
Followed by three washes as before, Hoechst stain diluted
in PBS was added and incubated for 10 min to allow for
the staining of the nucleus. The cells were washed once
with PBS and mounted onto a clean slide using GelMount
(Sigma-Aldrich). A period of 2 h was allocated for setting
to take place and the slides were then stored at 4 °C until
visualisation. Importantly, controls included cells treated
with the anti-CAT antibody (primary antibody) together
with the FITC-coupled secondary antibody and cells
treated with the secondary antibody only.
Flow cytometry- FACS™ analysis
In order to quantitatively determine cell surface LRP/LR
levels, flow cytometry was employed. Trypsin/Versene
(1X) was used to detach adherent cells, which were then
centrifuged at 150 x g for 10 min. Cells were re-
suspended and fixed in 4% PFA at 4 °C for 10 min. PFA
was discarded and cells were re-suspended in PBS which
allowed for the preparation of three cell suspensions,
one to which the primary anti-LRP/LR specific IgG1-
iS18 antibody was added, one to which anti-CAT anti-
body was added and one to which no antibody was
added (serving as the unstained control). All suspensions
were incubated in the dark for 1 h at room temperature.
Following three PBS washes by centrifugation at 2700 x
g for 5 min, the goat anti-human phycoerythrin (PE)-
coupled secondary antibody (abcam) was added to each
cell suspension and further incubated for 1 h at room
temperature. After the 1 h incubation, suspensions were
centrifuged at 2700 x g for 1 min and pellets washed
three times in PBS as previously described. The cell sus-
pensions were then analysed using the BD Accuri flow
cytometer and software. The experiment was performed
in triplicate.
SDS PAGE and Western blotting
Total LRP/LR levels were determined using sodium do-
decyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) as well as Western blotting. To perform SDS-
PAGE, 11 μg of total protein was used. Proteins that
were separated according to size by SDS-PAGE were
identified via Western blotting. The proteins resolved on
the polyacrylamide gel were transferred onto the polyvi-
nylidene fluoride (PVDF) membrane using 1X transfer
buffer (20% Methanol in 192 mM glycine and 25 mM
Tris) for 45 min at 350 mV and a semi-dry transferring
apparatus. Blocking buffer (3% BSA in 1X PBS Tween)
was then used to block the blotted membrane for 1 h in
order to prevent non-specific binding of primary andsecondary antibodies. Once blocked, the membrane was
probed with anti- LRP/LR specific primary antibody
IgG1-iS18 for 1 h. Prior to the incubation of the mem-
brane in the goat anti-human IgG- Horse radish perox-
idase (HRP) conjugated secondary antibody, three 1X
PBS Tween (0.1% Tween in 1X PBS) washes were per-
formed. A further three PBS Tween washes were per-
formed after incubation in the secondary antibody,
followed by the detection of HRP using an enhanced
chemiluminescent Clarity™ Western ECL Blotting Sub-
strate (BIORAD). The resulting fluorescence was de-
tected and visualised using the Chemidoc apparatus
(BIORAD). The experiment was executed in triplicate
and quantification was performed via densitometric ana-
lysis using ImageJ™ software.
Adhesion assay
In order to analyse the adhesive potential of the tumori-
genic cell lines to the basement membrane in vitro,
laminin-1 (10 μg/ml) was used to coat 96- microwell
plates, leaving uncoated wells to be used as negative
controls. After coating of the wells for 1 h and washing
with 1% BSA in the respective media, other protein
binding sites on the well were blocked using 100 μl of
0.5% BSA for 1 h. Cells were trypsinised and diluted in
serum-free culture media to a density of 4x105cells/ml
and added to the wells in order to assess the adhesive
potential. Furthermore, the cells pre-incubated with IgG1-
iS18 (0.2 mg/ml) and the anti-CAT antibody (0.2 mg/ml)
as the negative control were added to the relevant wells
in order to examine the effect the antibody might have
on the adhesive potential of the cells. The plates were
incubated at 37 °C for 1 h and thereafter the non-
adherent cells were washed off with PBS and the adher-
ent cells fixed with 4% PFA for 10 min. The adherent
cells were stained with 0.1% crystal violet for 10 min.
The stain was extracted using 2% SDS and the absorb-
ance of the extracted dye at 550 nm was assayed as a
measure of the adhesive potential using an ELISA reader.
The experiments were performed in triplicate.
Invasion assay
In vitro analysis of the ability of the tumorigenic cell
lines to invade the basement membrane in the absence
of the anti-LRP/LR specific antibody IgG1-iS18 and
when treated with the antibody was assessed using the
ECM- like Matrigel™ invasion assay.
Serum-free cold culture medium was used to dilute
the Matrigel™ and the diluted gel was dispensed into the
upper chamber of a 24 transwell plate (Corning, 8 μm
pores). The gel was allowed to solidify for 4 h at 37 °C.
After being trypsinised and harvested, the cells were di-
luted in serum-free culture media at a density of
1x106cells/ml. The cells were then incubated with IgG1-
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the negative control and loaded onto the upper-
Matrigel™ covered chamber. The lower chamber was
then filled with 500 μl of media containing 10% FCS for
the test and FCS-free media for the control and incu-
bated for 24 h at 37 °C. After removal of the lower and
upper chamber media, the cells were fixed with 100 μl
of 4% PFA for 15 min. Cells were then washed with
100 μl cold PBS and further stained using 0.5% toluidine
blue dye for 2 min. Non-invasive cells were removed
using a cotton swab. The dye was then extracted using
1% SDS and the absorbance measured at 620 nm using
an ELISA reader. The experiments were performed in
triplicate.
Statistical evaluation
The two-tailed student’s t-test with a confidence interval
of 95% was used in order to prove the statistical signifi-
cance of the results obtained, with p-values of less than
0.05 being considered significant. The degree of associ-
ation between LRP/LR levels and the adhesive/ invasive
potential of the cell lines was measured using Pearson’sFig. 1 Visualisation of cell surface LRP/LR levels of pancreatic cancer (AsPC-
in order to visualize the surface of the cancerous cells. a The cells were lab
the FITC-coupled secondary antibody which is specific for the primary anti
the anti-chloramphenicol acetyltransferase (CAT) antibody as the negative
antibody only, to indicate that no non-specific binding of the secondary ancorrelation coefficient. A positive coefficient was an indi-
cation of direct proportionality between the two vari-
ables; however a negative coefficient implied indirect/
inverse proportionality.
Results
Pancreatic cancer and neuroblastoma cells reveal LRP/LR
on the cell surface
Cell surface LRP/LR was visualised in order to confirm
that the tumorigenic cells did indeed display LRP/LR on
their surface and therefore play a pivotal role in the oc-
currence of metastasis due to the LRP/LR- laminin-1
interaction. LRP/LR was revealed on the cell surface of
the poorly invasive breast cancer control cell line as well
as the two experimental cell lines as indicated by the
green fluorescence in Fig. 1a. Cells were non- permea-
blized allowing for cell surface staining of LRP/LR and
the secondary antibody was shown to be specific for
anti-LRP/LR specific antibody IgG1-iS18 only, as
depicted by the control images B) and C) in Fig. 1. The
anti-CAT antibody was used as an effective negative con-
trol due to its ability to bind specifically to the1) and neuroblastoma (IMR-32) cells. The cells were non-permeabilized
elled with the primary antibody IgG1-iS18 which binds to LRP/LR and
body thus exhibiting green fluorescence. b The cells were labelled with
control. c The cells were labelled with the FITC coupled secondary
tibody occurred
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tein which is absent in mammalian cells.
High percentages of tumorigenic cells reveal LRP/LR on
the cell surface
As confirmed by confocal microscopy, the cells do in-
deed display LRP/LR on their cell surface, however
further quantification of the endogenous expression of
cell surface LRP/LR levels was required. Flow cytome-
try was therefore employed for this quantification. A
high percentage of cells within the specific cell popu-
lation that express LRP/LR on their cell surface were
revealed for all three cell lines. This is indicated by
the shift between the black (unlabelled) and red
(IgG1-iS18 and PE) peaks, as seen in Fig. 2a. Due to
the surface staining of the cells with anti-LRP/LR spe-
cific antibody IgG1-iS18 and a relevant fluorochrome-
conjugated secondary antibody, a change in theFig. 2 Detection of LRP/LR levels on the surface of pancreatic cancer and n
pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) cells. The black pea
cells labelled with goat anti-human phycoerythin (PE)-coupled secondary a
LR specific antibody IgG1-iS18 and the afore-mentioned secondary antibod
secondary antibody does not bind non-specifically. The shift observed betw
intensity thus the presence of LRP/LR on the cell surface of the cell lines un
protein levels on the surface of the three tumorigenic cell lines as a contro
anti-CAT primary antibody and goat anti-rabbit allophycocyanin (APC)-coup
labelled with the afore-mentioned secondary antibody only. No distinct sh
absence of the CAT protein on the surface of the cell lines under studyfluorescence intensity was observed. Approximately
98.33% of the poorly invasive MCF-7 cells displayed
cell surface LRP/LR whilst 97.18% of the AsPC-1 cells
and 81.82% of the IMR-32 cells displayed LRP/LR on
the cell surface. A shift in fluorescence intensity was
not observed in Fig. 2b, thus indicating that the CAT
protein was indeed absent on the surface of the three
cell lines under study.
Pancreatic cancer and neuroblastoma cells display
significantly higher cell surface LRP/LR levels in
comparison to the poorly-invasive breast cancer cells
The shift in fluorescence intensity was further analysed
using median statistics as a means of determining the
amount of cell surface LRP/LR present within the cell
population. Identical concentrations of primary (IgG1-
iS18) and secondary (PE) antibody were used to label 20
000 cells within a specific cell population over the sameeuroblastoma cells. a Quantification of LRP/LR on the surface of
k represents the unlabelled cells, whilst the blue peak represents the
ntibody. The red peak represents the cells labelled with both anti-LRP/
y. The inclusion of the unlabelled cells as a control, confirms that the
een the black and red peak indicates a change in fluorescence
der study. b Determination of chloramphenicol acetyltransferase
l. The blue peak represents cells that have been labelled with both
led secondary antibody, whilst the red peak represents the cells
ift is seen between the blue and red peak, thereby indicating the
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indicative of the differential expression of LRP/LR on
the cell surface. A significant difference in surface LRP/
LR levels were observed between the poorly invasive
MCF-7 cells and the AsPC-1 cells as well as between the
IMR-32 cells, as depicted in Fig. 3. When comparing the
two experimental cell lines, there was a significant differ-
ence in surface LRP/LR levels observed with the IMR-32
cells exhibiting the highest percentage of cell surface
LRP/LR.
Pancreatic cancer and neuroblastoma cells exhibit no
significant difference in total LRP/LR levels in comparison
to the poorly-invasive breast cancer control cell line
LRP/LR is not only located on the cell surface but it is
also found in the nucleus, including the perinuclear re-
gion and in the cytosol. Total LRP/LR levels across the
two tumorigenic cell lines as well in the poorly invasive
MCF-7 cells were determined via Western blot analysis.
Further insight on the relationship between the LRP/LR
levels, both surface and total and the adhesive and inva-
sive potential of the tumorigenic cells was obtained by
performing densitometric analysis.
As seen in Fig. 4a, LRP/LR was expressed by the three
cell lines, but a non- significant difference in total LRP/Fig. 3 Quantification of cell surface LRP/LR levels on pancreatic cancer (AsP
the primary IgG1-iS18 antibody and the anti-human phycoerythrin (PE) sec
with the median fluorescence intensity analysed as an indicator of the cell
AsPC-1 cells exhibit an approximate 2-fold increase in cell surface LRP/LR w
surface LRP/LR. This data is representative of three experimental triplicates.
deviation and p-values *p≤ 0.05, **p≤ 0.01, ***p ≤ 0.001LR levels were observed (Fig. 4b). The anti-LRP/LR
specific antibody IgG1-iS18 only detected the 37-kDa
laminin receptor precursor (LRP) form successfully and
β-actin served as the loading control.IgG1-iS18 significantly reduces the adhesive potential of
pancreatic cancer and neuroblastoma cells
The initiation of invasion and ultimately metastasis
occurs via the adhesion of a tumorigenic cell to the
basement membrane through the LRP/LR- laminin-1
interaction. The LRP/LR-laminin-1 interaction results
in the occurrence of additional interactions that enable
basement membrane degradation. The tumorigenic
cells were treated with IgG1-iS18 and anti-CAT (con-
trol) antibodies (0.2 mg/ml) and the absorbance read-
ings taken were a representation of the extent of cell
adhesion to laminin-1. The pancreatic cancer cells and
the neuroblastoma cells revealed a higher adhesive po-
tential than the poorly- invasive breast cancer (MCF-7)
control cell line, with the IMR-32 cells displaying the
highest adhesion to laminin-1 as shown in Fig. 5. How-
ever, when the cells were treated with the IgG1-iS18
antibody, there was a significant reduction in the adhe-
sive potential of both AsPC-1 and IMR-32 cell lines.C-1) and neuroblastoma (IMR-32) cells. The cells were labelled with
ondary antibody. 20 000 cells were analysed across all three cell lines,
surface LRP/LR levels. In comparison to the MCF-7 control cell line,
hilst the IMR-32 cells exhibit an approximate 4-fold increase in cell
The MCF-7 values were set to 100%. The error bars represent standard
Fig. 4 Detection of total LRP levels in pancreatic cancer (AsPC-1) and neuroblastoma (IMR-32) cells. a Western blot analysis was performed to detect
total 37-kDa LRP levels in all three cancer cell lines. β-actin was used as a loading control. b Densitometric quantification performed on these blots
revealed that there was no significant difference in total LRP/LR levels between the poorly invasive MCF-7 cells and the two experimental cell lines:
AsPC-1 and IMR-32. This data is representative of an average of three experiments. The values obtained from quantification of LRP were divided by the
values obtained from β-actin quantification and the resultant values were used to construct the above graph. The MCF-7 values were set to 100%. The
error bars represent standard deviation and Non-significant (N.S) p-value: p > 0.05
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were not significantly affected by the anti-CAT control
antibody, as expected.Invasion of pancreatic cancer and neuroblastoma cells is
significantly reduced by IgG1-iS18
Invasion of the basement membrane by the tumorigenic
cells is a pre-requisite for the translocation of the cell to
secondary sites within the body via the process of metas-
tasis. Matrigel™ invasion assays mimic the components
of the basement membrane, allowing for the determin-
ation of the invasive potential of the respective cell lines.
The three cell lines under study were treated with anti-
LRP/LR specific antibody IgG1-iS18 and anti-CAT con-
trol antibody (0.2 mg/ml). AsPC-1 and IMR-32 cells
proved to be significantly more invasive in comparison
to the poorly-invasive MCF-7 control cell line (Fig. 6).
Upon treatment with IgG1- iS18, the invasive potential
of the pancreatic cancer and neuroblastoma cells were
successfully reduced. The invasive potential of the
tumorigenic cell lines were not significantly affected by
the anti-CAT control antibody, as expected.Discussion
Laminin is a key glycoprotein of the basement mem-
brane and it is involved in the attachment, spreading,
migration and differentiation of normal and neoplastic
cells via the interaction with 37-kDa/67-kDa LRP/LR
[20]. The overexpression of the 37-kDa/ 67-kDa LRP/LR
in numerous tumorigenic cell lines has been implicated
in the enhancement of the LRP/LR-laminin-1 inter-
action, as indicated by several studies [21, 22]. This en-
hanced interaction is therefore responsible for invasion
of the basement membrane and consequent metastasis
[21, 22]. Therefore, inhibiting the LRP/LR-laminin-1
interaction may be effective in impeding metastasis. This
has recently been shown, where the anti-LRP/LR specific
antibody IgG1-iS18 has significantly reduced the adhe-
sive and invasive potential of cervical, lung, prostate,
colon, oesophageal, breast and liver cancer cells [10–12].
In addition, Zuber et al. [23] showed that downregulation
of LRP/LR with recombinant lentiviral plasmids express-
ing anti-LRP siRNAs, caused a reduction in invasive po-
tential of tumorigenic HT1080 fibrosarcoma cells. The
present study investigated the role of LRP/LR on the
metastatic potential of pancreatic cancer (AsPC-1) and
Fig. 5 IgG1-iS18 reduces the adhesive potential of AsPC-1 and IMR-32 cells to laminin-1. Absorbance was measured at 550 nm after an incubation
of one hour and after staining with crystal violet. CAT was used as a negative control. When treated with IgG1-iS18, the adhesive potential of the
AsPC-1 and IMR-32 cells decreased significantly. The MCF-7 untreated value was set to 100%. The error bars represent standard deviation
and p-values *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, Non-significant (N.S): p > 0.05
Rebelo et al. BMC Cancer  (2016) 16:917 Page 8 of 11neuroblastoma (IMR-32) cells with respect to adhesion
and invasion and whether targeting the LRP/LR-laminin-1
interaction using the anti-LRP/LR specific antibody IgG1-
iS18 may impede the metastatic potential of the two can-
cer cell lines.
All three cell lines displayed LRP/LR on the cell sur-
face as revealed by confocal microscopy. This technique
is limited by the fact that it is not quantitative, therefore
further analysis using flow cytometry as well as fluores-
cence intensity was required in order to establish the
level at which LRP/LR is displayed on the cell surface of
the tumorigenic cell lines. A high percentage of cells
with LRP/LR on their cell surface were displayed in the
three cell lines under study. In comparison to the con-
trol cell line, it was observed that AsPC-1 cancer cells
revealed significantly higher and IMR-32 cells revealed
the highest cell surface LRP/LR levels. AsPC-1 and IMR-
32 cancer cells are classified as metastatic, thus the high
percentage of these cells displaying cell surface LRP/LR
may be owing to their aggressiveness, with respect to
their invasive potential.
All three cancer cell lines did display relatively similar
percentages of cells that contain cell surface LRP/LR;
however upon additional quantification of cell surface
LRP/LR levels by analysis of fluorescence intensity, itwas observed that the level of LRP/LR displayed on the
cell surface of the invasive cells in comparison to the
poorly invasive cells was significantly higher.
Further analysis by Western blotting revealed the ex-
pression of the 37-kDa LRP in all three cancer cell lines,
but upon densitometric analysis, the poorly invasive and
invasive cell lines revealed similar total LRP/LR levels
and no significant differences were therefore observed.
Total LRP/LR levels refer to cytosolic and nuclear
LRP/LR in the tumorigenic cells, which serves to facili-
tate translational processes and maintain nuclear struc-
tures, respectively. Therefore, although there was no
significant difference in total LRP/LR levels between the
invasive and poorly invasive cell lines, cell surface LRP/
LR levels are of importance for adhesion and consequent
invasion of the cancer cell lines under study.
The correlation between cell surface LRP/LR levels to
the adhesive and invasive potential of pancreatic cancer
(AsPC-1) and neuroblastoma (IMR-32) cells was ana-
lysed and a high correlation was detected (Table 1). The
respective correlation coefficients indicate a directly pro-
portional and positive relationship between the two fac-
tors. This therefore confirms that the enhanced adhesive
and invasive potential of the metastatic cancer cell lines
under study is as a result of the high cell surface LRP/
Fig. 6 IgG1-iS18 reduces the invasive potential of AsPC-1 and IMR-32 cells through the ECM-like Matrigel™. Absorbance was measured at 620 nm
after an incubation of 24 h and after staining with toluidine blue. CAT was used as a negative control. When treated with IgG1-iS18, the invasive
potential of the AsPC-1 and IMR-32 cells was significantly decreased, respectively. The MCF-7 untreated value was set to 100%. The error bars
represent standard deviation and p-values *p≤ 0.05, **p ≤ 0.01, ***p≤ 0.001, Non-significant (N.S): p > 0.05
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for the adhesive to invasive potential serves as confirm-
ation that the occurrence of adhesion is a pre-requisite
for invasion. A non- significant difference in total LRP/
LR levels between the cancer cell lines under study was
observed and therefore only cell surface LRP/LR levels
were taken into consideration in the calculations of
Pearson’s correlation coefficients.
The variation in the adhesive and invasive potential of
both AsPC-1 and IMR-32 cell lines in comparison to the
MCF-7 control cell line and how this variation may be
due to differences in cell surface LRP/LR levels are dem-
onstrated in the present study. Affirmation that the
LRP/LR-laminin-1 interaction facilitates adhesion but
also stimulates the secretion of enzymatic substances
that degrade the basement membrane such as type IV
collagenase (including matrix metalloproteinases,
MMPs) is in agreement with reported results, thus sug-
gesting the promotion of invasion and migration
through the body [20]. Hence, the higher cell surfaceTable 1 Pearson’s correlation coefficients between cell surface
LRP/LR levels and the adhesive and invasive potential of







AsPC-1 0.996 0.981 0.994
IMR-32 0.761 0.993 0.833LRP/LR levels detected for IMR-32 cells could be re-
sponsible for the higher adhesion of the metastatic cell
to laminin-1 on the basement membrane. However, the
neuroblastoma cells did not exhibit an increased invasive
potential as anticipated from the high cell surface LRP/
LR levels and adhesive potential. This could possibly be
as a result of the expression of tissue inhibitors of metal-
loproteinases (TIMPs). TIMPs could therefore inhibit
the activity of type IV collagenase [24], hence degrad-
ation of type IV collagen in the Matrigel is prevented,
and thus preventing the invasion of IMR-32 cells in vitro
[12]. The AsPC-1 cancer cells displayed high cell surface
LRP/LR levels in comparison to the MCF-7 control cell
line but lower expression levels than the IMR-32 cells.
However, these elevated cell surface LRP/LR levels re-
sulted in the enhanced adhesive and invasive potential of
AsPC-1 cells.
It was further observed that the IgG1-iS18 antibody
significantly decreased the adhesive potential of both
AsPC-1 and IMR-32 cells. The invasive potential of both
AsPC-1 and IMR-32 cells were also significantly reduced
upon IgG1-iS18 application. The inhibition of adhesion;
a mandatory step for invasion of the ECM as indicated
by the high Pearson’s correlation coefficients, may be the
reason for the significant decrease in invasive potential.
These results suggest that the cleavage of the basal lam-
ina is significantly enhanced by the LRP/LR-laminin-1
interaction, thus facilitating the process of invasion and
Rebelo et al. BMC Cancer  (2016) 16:917 Page 10 of 11migration. Furthermore, the exact mechanism by which
the anti-LRP/LR specific antibody IgG1-iS18 impedes ad-
hesion and invasion is not fully understood. However, it is
possible that the two laminin binding domains (amino
acid 160–180 and 205–229) on the 37-kDa/67-kDa lam-
inin receptor LRP/LR may be directly blocked by the anti-
body or indirectly leading to conformational changes of
the laminin binding domains, thereby changing the affinity
of the binding domains for laminin.
Different cancer types exhibit different behavioural
characteristics; therefore one cannot speculate that the
IgG1-iS18 antibody will significantly impede the meta-
static potential of all cancer types in the same manner.
However, the results of the current study will indicate
the use of the antibody as a possible therapeutic tool for
the treatment of metastatic pancreatic cancer and neuro-
blastoma cells. Since LRP/LR is crucial for numerous
physiological processes, targeting this receptor may
prove difficult as its inhibition may further compromise
the health of the patient. Therefore, studies concerning
appropriate delivery systems for the IgG1-iS18 antibody
should be conducted. Successful animal trials may fur-
ther illustrate that this antibody is a possible therapeutic
tool in the fight against metastatic cancer.
Conclusion
Anti-LRP/LR specific antibody IgG1-iS18 significantly
affected the behaviour of AsPC-1 and IMR-32 cancer
cells by impeding their adhesive and invasive potential
in vitro, therefore suggesting that this antibody may act
as a possible therapeutic tool for the treatment of meta-
static pancreatic cancer and neuroblastoma. Future work
will involve investigating the efficacy of the IgG1-iS18
antibody as a therapeutic tool for the prevention of sev-
eral metastatic cancer types, using in vivo mouse xeno-
graft models.
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